We combine an outstanding biobank of patient-derived organoids with leading AI-profiling methodology to reinvent cancer drug discovery.

Within project ACHILLEUS, we develop a novel high-content drug screening platform. Our platform combines high throughput imaging of drug-treated, patient-derived organoids. In our groundbreaking approach, we integrate large-scale image-based screening with cutting-edge AI-based data processing and phenotypic data analysis. Our innovative knowledge base guides us in a data-driven way to identify new drug targets and develop drug candidates targeting critical vulnerabilities in cancer, particularly cancer stemness signaling. The stemness of neoplastic cells as the root cause of complications in cancer has been proposed as a major factor in treatment resistance and high relapse rates and is thus at the core of our mission to improve the lives of cancer patients. Using our biological insights, our screening platform, and our AI processing pipeline, we and our future partners aim to make AI-driven drug discovery a reality and bring new therapeutics to the market and, finally, to cancer patients in need.